Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
Leap halves head count amid 'difficult market environment'
Leap Therapeutics is laying off half of its staff as it narrows the focus of its lead cancer drug.
James Waldron
May 13, 2025 9:10am
Exact Sciences kicks off launch of next-gen Cologuard Plus test
Mar 31, 2025 6:00am
Leap crashes as midphase data mark end of gastric cancer program
Jan 28, 2025 8:31am
JPM25: Guardant posts 31% sales gain as cancer blood tests grow
Jan 13, 2025 9:19am
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Dec 10, 2024 4:05pm
Guardant awarded $292M in false advertising suit against Natera
Nov 26, 2024 10:45am
